Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jobs Report Highlighted During Holiday-Shortened Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (June) Construction ...

DDD : 4.03 (-1.71%)
DZSI : 1.2900 (-5.15%)
PXD : 269.62 (+0.73%)
MSM : 84.93 (+0.80%)
SLP : 43.19 (-2.37%)
RDUS : 17.83 (-0.22%)
STZ : 248.16 (+0.03%)
KALV : 14.96 (-1.90%)
U.S. Inflation News Due out Next Week

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...

FLOW.TO : 0.1650 (-5.71%)
GRA.TO : 2.48 (+1.64%)
CXI.TO : 25.89 (-0.88%)
ORCL : 139.03 (-2.51%)
CASY : 380.30 (-0.78%)
INNV : 5.96 (+1.02%)
EPM : 5.78 (+0.52%)
TSP : 0.2500 (-5.66%)
CBRL : 46.73 (+4.85%)
REVG : 24.33 (-8.47%)
IBEX : 17.07 (-0.23%)
ADBE : 563.09 (-0.61%)
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 14.96 (-1.90%)
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 14.96 (-1.90%)

Barchart Exclusives

Analysts Are All-in on Nvidia's Biggest AI Chip Rival
This top AI chip rival to Nvidia is earning bullish praise from analysts amid the growing demand for AI chips. Should you buy the dip? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar